NASDAQ: KA - Kineta, Inc.

Rentabilité sur six mois: -18.63%
Secteur: Healthcare

Calendrier des promotions Kineta, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Kineta, Inc., a clinical-stage biotechnology company, develops immunotherapies in the field of immuno-oncology, cancer, neurology, and arenaviruses. The company is developing KVA12123, an anti-VISTA antagonist mAb immunotherapy, which is in Phase 1/2 clinical trials for the treatment of solid tumors, including non-small cell lung cancer, ovarian cancer, colorectal cancer, colon cancer, pancreatic cancer, and gastric cancer.

plus de détails
It is also developing anti-CD27 agonist mAb immunotherapy, which is in Phase 1 clinical trials for the treatment of advanced solid tumors, such as renal cell carcinoma, ovarian cancer, and colorectal cancer. In addition, the company develops immunotherapies for pain management and anti-viral therapy for the treatment of emerging diseases. Kineta, Inc. has collaboration and license agreements with MSD International Business GmbH, and GigaGen, Inc. The company was formerly known as Lecura, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2016-02-11
ISIN US49461C1027
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Дивиденд ао 10.01
Сайт https://kinetabio.com
Цена ао 0.5521
Changement de prix par jour: 0% (0.4801)
Changement de prix par semaine: 0% (0.4801)
Changement de prix par mois: 0% (0.4801)
Changement de prix sur 3 mois: -14.27% (0.56)
Changement de prix sur six mois: -18.63% (0.59)
Changement de prix par an: -86.77% (3.63)
Evolution du prix sur 3 ans: -85.09% (3.22)
Evolution du prix sur 5 ans: -74.6% (1.89)
Evolution des prix sur 10 ans: 0% (0.4801)
Evolution des prix depuis le début de l'année: 0% (0.4801)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 8.12 1
P/BV 14.45 1
P/E 0 0
EV/EBITDA -2.52 0
Total: 4

Efficacité

Nom Signification Grade
ROA, % -137.14 0
ROE, % -487.85 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0.5 5
Total: 2.35

Devoir

Nom Signification Grade
Debt/EBITDA -0.0838 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 8.84 2
Rentabilité Ebitda, % -73.68 0
Rentabilité EPS, % -99.21 0
Total: 0.4
Plus de détails

Établissements Volume Partager, %
Armistice Capital, LLC 825792 7.53
Vanguard Group Inc 151380 1.38
FMR, LLC 123719 1.13
Geode Capital Management, LLC 50584 0.46
Northern Trust Corporation 36880 0.34
Stifel Financial Corporation 21853 0.2
Financial Advocates Investment Management 21744 0.2
Blackrock Inc. 19957 0.18
Renaissance Technologies, LLC 19044 0.17
ELEMENT POINTE ADVISORS, LLC 17696 0.16



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Craig W. Philips President & Secretary 541.67k 1961 (64 année)
Ms. Pauline Kenny Esq., J.D. Advisor 349.72k 1974 (51 année)
Mr. Keith A. Baker Chief Financial Officer 485.75k 1967 (58 années)
Dr. Thierry Guillaudeux Ph.D. Chief Scientific Officer N/A 1968 (57 années)
Mr. Gary Gentges Executive Vice President of Corporate Development

Adresse: United States, Seattle. WA, 219 Terry Ave. N - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://kinetabio.com